Department of Clinical Pharmacy and Biopharmacy, Karol Marcinkowski University of Medical Sciences Poznań, Poland.
Department of Clinical Pharmacy and Biopharmacy, Karol Marcinkowski University of Medical Sciences Poznań, Poland.
Pharmacol Rep. 2014 Feb;66(1):159-64. doi: 10.1016/j.pharep.2013.06.010. Epub 2014 Feb 5.
Tramadol/paracetamol is a fixed-dose combination prescribed for the relief of moderate to severe pain. The combination acts synergistically and guarantees the rapid onset of paracetamol and the prolonged analgesic effect of tramadol with good tolerability. These drugs are often used in various formulations in the treatment of patients with postoperative pain, e.g. after stomach resection. Gastrectomy leads to pathophysiological changes within the alimentary tract, which may affect the process of drug absorption. The aim of the research was an analysis of the pharmacokinetics of tramadol/paracetamol from effervescent and conventional tablets in patients after total gastrectomy.
The research was carried out on patients after gastrectomy with Roux-en-Y reconstruction. The patients received two tramadol/paracetamol fixed-dose combination tablets in a single orally administered dose of 75/650 mg (2 × 37.5/325 mg). The patients were subjected to one of the two study drug group with: I. effervescent tablet (ET) (n = 14; mean [SD] age, 63.4 [10.1] years; weight, 75.5 [15.3]kg; and BMI, 26.0 [4.6]kg/m(2)) and II. conventional tablet (CT) (n = 12; mean [SD] age, 66.8 [7.7] years; weight, 79.8 [17.8]kg; and BMI, 27.4 [5.3]kg/m(2)). Blood samples were collected within 10 h after the drug administration. The plasma concentrations of tramadol and paracetamol were measured with validated HPLC (high-performance liquid chromatography) method with UV detection.
The comparison of the paracetamol and tramadol C(max) ratio for the ET group with that of the CT group gave ratios of 1.16 [90% confidence interval (CI) 1.06, 1.27] and 0.86 (90% CI 0.72, 1.02), respectively. The comparison of the paracetamol and tramadol AUC(0-t) ratio for the ET group with that of the CT group showed ratios of 0.99 (90% CI 0.88, 1.10) and 1.00 (90% CI 0.82, 1.22), respectively. The comparison of the difference for the effervescent and conventional formulation gave an estimated decrease in t(max) of 0.5 h for paracetamol and 0.13 h for tramadol.
In view of the changes in the pharmacokinetics of paracetamol and tramadol in the patients after gastric resection for both formulations compared the conventional tablet seems to be more appropriate due to the comparable rate of absorption of both substances, higher concentrations of tramadol and comparable exposure to paracetamol.
曲马多/对乙酰氨基酚是一种固定剂量的复方制剂,用于缓解中度至重度疼痛。该组合协同作用,保证了对乙酰氨基酚的快速起效和曲马多的延长镇痛效果,且具有良好的耐受性。这些药物通常以各种制剂用于治疗术后疼痛的患者,例如胃切除术后。胃切除术后会导致消化道发生病理生理学变化,这可能会影响药物吸收过程。本研究的目的是分析全胃切除术后患者使用泡腾片和普通片的曲马多/对乙酰氨基酚的药代动力学。
本研究在接受 Roux-en-Y 重建的胃切除术后患者中进行。患者单次口服给予 75/650mg 双氯芬酸钠/对乙酰氨基酚固定剂量复方制剂两片(2×37.5/325mg)。患者被分为两组中的一组:I. 泡腾片(ET)(n=14;平均[SD]年龄 63.4[10.1]岁;体重 75.5[15.3]kg;BMI 26.0[4.6]kg/m²)和 II. 普通片(CT)(n=12;平均[SD]年龄 66.8[7.7]岁;体重 79.8[17.8]kg;BMI 27.4[5.3]kg/m²)。给药后 10 小时内采集血样。采用经验证的高效液相色谱(HPLC)法结合紫外检测测定曲马多和对乙酰氨基酚的血浆浓度。
与 CT 组相比,ET 组的对乙酰氨基酚和曲马多 Cmax 比值为 1.16(90%置信区间[CI]为 1.06,1.27)和 0.86(90%CI 为 0.72,1.02)。与 CT 组相比,ET 组的对乙酰氨基酚和曲马多 AUC(0-t)比值为 0.99(90%CI 为 0.88,1.10)和 1.00(90%CI 为 0.82,1.22)。泡腾片和普通片的差异比较表明,对乙酰氨基酚的 tmax 估计减少了 0.5 小时,曲马多的 tmax 估计减少了 0.13 小时。
鉴于胃切除术后两种制剂的对乙酰氨基酚和曲马多药代动力学的变化,与普通片相比,普通片似乎更合适,因为两种物质的吸收速度相当,曲马多的浓度更高,对乙酰氨基酚的暴露量相当。